Belzutifan
Welireg (belzutifan) is a small molecule pharmaceutical. Belzutifan was first approved as Welireg on 2021-08-13. It is used to treat von hippel-lindau disease in the USA. It is known to target endothelial PAS domain-containing protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Welireg
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Belzutifan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| WELIREG | Merck & Co | N-215383 RX | 2021-08-13 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| welireg | New Drug Application | 2024-01-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| von hippel-lindau disease | — | D006623 | Q85.83 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BELZUTIFAN, WELIREG, MERCK SHARP DOHME | |||
| 2028-08-13 | ODE-364 | ||
| 2026-12-14 | I-931 | ||
| 2026-08-13 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 11 | 7 | 5 | — | 1 | 21 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 11 | 6 | 5 | — | 1 | 20 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 3 | 1 | — | — | — | 4 |
| Neoplasms | D009369 | — | C80 | 1 | 2 | — | — | — | 3 |
| Von hippel-lindau disease | D006623 | — | Q85.83 | — | 2 | — | — | 1 | 3 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Pheochromocytoma | D010673 | — | — | — | 1 | — | — | — | 1 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 1 | — | — | — | 1 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
| Clear cell adenocarcinoma | D018262 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Belzutifan |
| INN | belzutifan |
| Description | Belzutifan, sold under the brand name Welireg, is an anti-cancer medication used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. It is taken by mouth. Belzutifan is an hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor.
|
| Classification | Small molecule |
| Drug class | hypoxia-inducible factor (HIF) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F |
Identifiers
| PDB | — |
| CAS-ID | 1672668-24-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4585668 |
| ChEBI ID | — |
| PubChem CID | 117947097 |
| DrugBank | DB15463 |
| UNII ID | 7K28NB895L (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
EPAS1
EPAS1
Organism
Homo sapiens
Gene name
EPAS1
Gene synonyms
BHLHE73, HIF2A, MOP2, PASD2
NCBI Gene ID
Protein name
endothelial PAS domain-containing protein 1
Protein synonyms
Basic-helix-loop-helix-PAS protein MOP2, bHLHe73, Class E basic helix-loop-helix protein 73, EPAS-1, HIF-1-alpha-like factor, HIF-1alpha-like factor, HIF-2-alpha, HIF2-alpha, HLF, hypoxia-inducible factor 2 alpha, Hypoxia-inducible factor 2-alpha, Member of PAS protein 2, PAS domain-containing protein 2
Uniprot ID
Mouse ortholog
Epas1 (13819)
endothelial PAS domain-containing protein 1 (P97481)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Welireg – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 647 documents
View more details
Safety
Black-box Warning
Black-box warning for: Welireg
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
759 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use